MEGIN, the global leader in Magnetoencephalography (MEG) technology, is pleased to announce the successful raising of $3,200,000 in funding aimed at further advancing brain health solutions. This significant investment underscores our commitment to enhancing the standard of care for neurological health and improving quality of life for patients across the globe. With over 30 years of experience in the field, MEGIN has become synonymous with innovation in detecting and visualizing brain function, partnering with clinicians, scientists, and healthcare organizations to transform neuroscience research into accessible clinical applications. This new funding will enable MEGIN to accelerate the development of next-generation MEG technology and expand our customer-centric organization, ensuring that cutting-edge solutions are not merely concepts in laboratories but are translated into clinical practice effectively and efficiently. Our mission is to provide an exceptional experience for our clients, raising both awareness and the utilization of MEG across various healthcare settings. By doing so, we aim to empower healthcare providers with the tools necessary to make informed decisions that profoundly impact patient outcomes. As we continue to grow our footprint with teams established in Finland, the UK, USA, and Japan, this funding marks a pivotal step towards solidifying MEGIN's role as a leader in the field and a dedicated partner in advancing brain health. We look forward to collaborating with our stakeholders to make MEG technology more accessible for healthcare professionals worldwide.





